Impact of the council of europe resolution on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients

H P A Scheepers; V Neerup Handlos; S Walser; M D B Schutjens; C Neef

doi:10.14748/ahp.v5i1.6142

Impact of the council of europe resolution on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients

H P A Scheepers, V Neerup Handlos, S Walser, M D B Schutjens, C Neef

Abstract

Introduction and objective: The regulation of pharmacy preparations, especially for standards for quality assurance and safety, is not harmonised across Europe and falls under the national competencies of individual states. There are concerns about quality control and safety for the medicinal products made in pharmacies, which is widespread in European countries. There are, however, good reasons to continue this practice, which is able to tailor preparations to the specific needs of a particular patient or patient group and to provide a supplementary source of supply when an industrially manufactured product, which is authorised for marketing is not available or when there are temporary shortages of licensed medicines. In seeking to provide guidelines for legislation and acting on the advice of an expert group dealing in pharmaceutical practices, the Committee of Ministers of the Council of Europe passed a resolution in 2011. The Council of Europe Resolution provides authorities and pharmacists with the means to reinforce safety measures for medicinal products prepared in pharmacies and to harmonise quality assurance and safety standards. It dealt with aspects of pharmacy preparation such as quality standards for preparation and distribution, marketing authorisation, product dossiers, labelling, reporting, and safety. In 2013 and 2014 the Committee of Experts carried out a survey to evaluate the impact of the resolution within a cross section of member states,
Methods: In the resolution of 2011 the member states were recommended to adapt their legislation in line with its provisions. The survey that was carried out in 2013 and 2014 followed the recommendations in the reso-lution. A questionnaire was made and sent to a
cross section of member states.
Results: Among the member states involved, the results of this survey show a clear commitment to imple-ment the recommendations of the resolution.
Conclusions: This report presents the results of the survey with a discussion of outstanding issues.

Full Text

References

Scheepers HPA, Busch G, Hofbauer E, et al. Abridged survey report on quality and safety assurance standards for the preparation of medicinal products in Pharmacies. Pharmeuropa 2010;22.

“Promoting Standards for the Quality and Safety Assurance of Pharmacy-Prepared Medicinal Products for the Needs of Patients”—Expert Workshop Proceedings (24 September 2009, European Directorate for the Quality of Medicines & Health-Care (EDQM), Council of Europe, in Strasbourg). http://www. edqm.eu/en/quality-and-safety-standards-1244.html

Council of Europe Committee of Ministers Resolution CM/ResAP(2011)1 on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients. https://wcd.coe.int/ViewDoc.jsp?id=1734101

Scheepers HPA, Langedijk J, Neerup Handlos V, et al. Legislation on the preparation of medicinal products in European pharmacies and the Council of Europe Resolution. Eur J Hosp Pharm 2016;0:1–6. doi:10.1136/ejhpharm-2016-001016

Scheepers HPA, Neerup Handlos V, Schutjens MH, et al. Inspectorate surveillance of preparing and distributing pharmacies in The Netherlands. Eur J Hosp Pharm Published Online First: 21 Jul 2016. doi:10.1136/ejhpharm-2015-000869

Medicines and Healthcare Products Regulatory Agency, MHRA, London, Regulating Medicines and medical devices, The supply of unlicensed medical products (“specials”), MHRA Guidance Note 14. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/373505/The_ supply_of_unlicensed_medicinal_products__specials_pdf

CDC. Centers for Disease Control and Prevention, Multistate Outbreak. Multistate Outbreak of Fungal Infection Associated with Injection of Methylprednisolone Acetate Solution from a Single Compounding Pharmacy—United States, 2012.

US Food and Drug Administration (FDA). CDC and ADPH investigate outbreak at Alabama hospitals; products recalled.(29 March 2011).—http://www.fda.gov/Safety/Recalls/ucm249068.htm

Wolfson H. Investigators piecing together tainted IV puzzle after deaths in Alabama hospitals. The Birmingham News (3 April 2011). http://blog.al.com/spotnews/2011/04/investiga-tors_piecing_together.html

DOI: http://dx.doi.org/10.14748/ahp.v5i1.6142